US EditionNovartis Signs $2.2 Billion Deal with Arrowhead to Develop Alpha-Synuclein Drug for Parkinson’s Disease
Summary by GeneOnline News
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Novartis Signs $2.2 Billion Deal with Arrowhead to Develop Alpha-Synuclein Drug for Parkinson’s Disease
Novartis has entered into a $2.2 billion agreement with […] The post Novartis Signs $2.2 Billion Deal with Arrowhead to Develop Alpha-Synuclein Drug for Parkinson’s Disease first appeared on GeneOnline News. The post Novartis Signs $2.2 Billion Deal with Arrowhead to Develop Alpha-Synuclein Drug for Parkinson’s Disease appeared first on GeneOnline News.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
